Dyadic and Fermbox Bio Launch First Product Under Expanded Collaboration: Animal-Origin-Free Recombinant DNase I (RNase-Free)

Dyadic Applied BioSolutions (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company producing precision-engineered, animal-free proteins and enzymes for life ...
The Manila Times

Dyadic to Report 2025 Full Year Financial Results and Host Conference Call on Wednesday, March 25, 2026

Dyadic International, Inc. d/b/a Dyadic Applied BioSolutions ('Dyadic', 'we', 'us', 'our', or the 'Company') (Nasdaq: DYAI), a global biotechnology company focused on the scalable production of ...
The Manila Times

Dyadic Applied BioSolutions and Inzymes ApS Announce Planned 2026 Commercialization of Non-Animal Dairy Enzyme Following Achievement of Develop…

Dyadic Applied BioSolutions ('Dyadic”, 'we”, 'us”, 'our”, or the 'Company”) (NASDAQ: DYAI), a global biotechnology company ...
Seeking Alpha

Dyadic International, Inc. Announces Strategic Rebrand to Dyadic Applied BioSolutions

Reflects the Company’s strategic focus on commercializing non-therapeutic proteins and unlocking long-term value from its C1 and Dapibus™ gene expression platforms JUPITER, Fla.--(BUSINESS WIRE)-- ...
Nasdaq

Dyadic International, Inc. CEO to Present at 2025 World Vaccine Congress on Advancements in Biomanufacturing for Vaccines

Dyadic International will present on its C1 platform at the 2025 World Vaccine Congress, focusing on avian influenza and preclinical research. Dyadic International, Inc., a biotechnology company ...
Seeking Alpha

Dyadic International, Inc. Announces Proposed Public Offering of Common Stock

JUPITER, Fla., July 30, 2025 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (DYAI), a global biotechnology company focused on the scalable production of high-value, precision engineered functional ...